The European Patent Office (EPO) has granted patent EP3578654B1, titled 'Method for Specific Isolation of Nucleic Acids of Interest,' with an effective date of March 18, 2026. The patent is designated for use in multiple European countries and lists Franck Tarendeau as the inventor. This grant pertains to a specific method within the C12N classification, which relates to molecular biology and genetic engineering.

This patent grant signifies a new intellectual property right in the field of biotechnology. While not a regulatory rule imposing obligations on companies, it affects the landscape for research and development in nucleic acid isolation. Companies operating in the EU, particularly those involved in drug manufacturing, medical device development, or pharmaceutical research, should be aware of this patent to ensure their activities do not infringe upon the granted claims. No immediate compliance actions are required, but legal and R&D departments should review the patent's scope for potential licensing or freedom-to-operate considerations.